Game-changing technologies

At Unither, innovation primarily aims to address real medical needs: improving treatment tolerance, simplifying use, securing processes, and facilitating access to care. Our technology platforms are designed from the outset to be industrializable, compliant with regulatory requirements, and scalable, in order to quickly deliver reliable solutions to patients and our clients in the pharmaceutical industry.

Our innovation models

Unither develops technology platforms that improve the access, safety, and efficacy of treatments: Euroject® for single-dose injectable administration of vaccines and biologics using BFS, Carragelose® / Eyeleen® to better stabilize the tear film in cases of dry eye, Sol-Gel™ for eye drops that gel in-situ and prolong the therapeutic effect, and Uniflash® for rapid oro-mucosal administration as a non-injectable alternative.

Sol-Gel™ - Ophthalmology

A formulation platform designed to optimize drug release, bioavailability, and patient comfort in ophthalmic eye drops.

Got questions? - Consult our FAQ

Yes, in many cases: it is a single-dose, ready-to-inject device. It offers cost reduction and reduced handling and ensures efficient volume delivery (0.47–0.49 mL delivered according to tests). It also addresses vaccine equity issues: no glass, simplified logistics, and greater facility for healthcare providers.

Unither Pharmaceuticals is the world leader in Blow-Fill-Seal (BFS) technology and a specialist in sterile liquid formats. Our presence in Europe, North and South America, and Asia ensures volume security, supply continuity, and proximity to your markets.

With robust cGMP processes, expertise in international regulations, and an efficient co-development model, Unither accelerates and supports your projects, from formulation to commercial manufacturing.

Our patented Sol-Gel™ technology allows the formulation of liquid ophthalmic hydrogels for production, which gel upon contact with tear fluid thanks to gellan gum. This property increases patient comfort, prolongs drug release time, and offers high bioavailability. Sol-Gel™ requires less active ingredient than traditional eye drops, which limits adverse effects. The first application, Solmyd™, offers effective mydriasis in a single instillation, instead of several successive drops.

Yes. Unither develops and manufactures small batches prior to industrial scale-up to ensure product performance and efficient industrialization.

Small volumes are handled at a dedicated, flexible site designed for small-batch production, in strict compliance with international pharmaceutical standards (GMP).
This approach allows you to verify the formulation, stability, and industrial feasibility of a product before transfer to our commercial production sites.